IP Library Granted Patent US 8,263,072
Granted Patent B2
US 8,263,072 · App. 12/665,270 · Granted Sep 11, 2012

ADAMTS4 as a blood biomarker and therapeutic target for chronic renal failure

Assignee: Genera Istrazivanja, d.o.o.
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 8,263,072
App. No.
12/665,270
Granted
Sep 11, 2012
Kind
B2
Abstract

ADAMTS4 is found to be useful as a blood biomarker for chronic renal failure and also as a therapeutic target for treating chronic renal failure in a human individual. A change in the level of expression of selected genes as disclosed herein in kidney tissue of an individual may also be used to diagnose chronic renal failure in an individual.

Claims (6)

1. A method of treating chronic renal failure in a human individual in need of treatment thereof comprising the step of:

administering to the individual an antibody to human ADAMTS4;

wherein said antibody is administered in an amount effective to reduce the level of ADAMTS4 in the blood.

2. The method according to claim 1 , wherein the antibody to ADAMTS4 is administered parenterally.

3. The method according to claim 2 , wherein the antibody to ADAMTS4 is administered intravenously.

4. The method according to claim 1 , wherein said individual in need of treatment for chronic renal failure is a dialysis patient.

Assignments (2)
CHANGE OF NAME Recorded Feb 16, 2010
From: GENERA DOO
To: GENERA ISTRAZIVANJA D.O.O.
Reel/Frame 024001/0692 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Feb 5, 2010
From: GRGUREVIC, LOVORKA; VUKICEVIC, SLOBODAN
To: GENERA D.O.O.
Reel/Frame 023918/0266 →
Continuity (2)
Provisional Application 60936850 · Jun 22, 2007
Related Publication 20100254997A1 · Oct 7, 2010